Use of systemic therapies for psoriasis in the COVID-19 era

J Dermatolog Treat. 2020 May 27;1-14. doi: 10.1080/09546634.2020.1775774. Online ahead of print.

Abstract

Background: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.

Objective: The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic.

Methods: Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized.

Results: The AAD,NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy.

Conclusion: Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis.

Keywords: Biologic; COVID-19; Immunosuppressant; Psoriasis; Systemic treatment.